UTI Asset Management Company Limited has informed the Exchange about Agreements
UTIAMC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
UTI AMC's Board approved unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025). On a standalone basis, total revenue from operations rose to ₹436.88 crore (vs ₹386.56 crore in Q1 FY25, up ~13%) and profit after tax grew to ₹216.13 crore (vs ₹185.81 crore, up ~16%), with EPS at ₹16.88 vs ₹14.60. On a consolidated basis, PAT actually dipped slightly to ₹253.86 crore (from ₹274.30 crore) due to a ₹9.72 crore net loss on fair value changes that wasn't present a year ago. The Board also approved a ₹45 crore unsecured working capital loan to its wholly owned subsidiary UTI Alternatives Private Limited, repayable by March 31, 2028, at 1-year SBI MCLR-linked interest rate. The statutory auditor (BSR & Co. LLP) issued a clean limited review report with no qualifications or observations.
Standalone results show healthy double-digit growth in revenue and profit, reflecting steady asset management business performance. The small consolidated PAT dip is a watch item driven by mark-to-market fair value changes, not core operations. The ₹45 crore inter-corporate loan to the wholly owned subsidiary is a routine related-party transaction at arm's length and unlikely to materially affect shareholders, though it deploys some of the company's cash into the alternatives arm.